Literature DB >> 12930144

3'-C-branched-chain-substituted nucleosides and nucleotides as potent inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.

Veerle Vanheusden1, Hélène Munier-Lehmann, Matheus Froeyen, Laurence Dugué, Arne Heyerick, Denis De Keukeleire, Sylvie Pochet, Roger Busson, Piet Herdewijn, Serge Van Calenbergh.   

Abstract

Thymidine monophosphate kinase (TMPK) of Mycobacterium tuberculosis (TMPKmt) represents an attractive target for blocking the bacterial DNA synthesis. In an attempt to find high-affinity inhibitors of TMPKmt, a cavity in the enzyme at the 3'-position was explored via the introduction of various substituents at the 3'-position of the thymidine monophosphate (dTMP) scaffold. Various 3'-C-branched chain substituted nucleotides in the 2'-deoxyribo (3-6) and ribo series (7, 8) were synthesized from one key intermediate (23). 2'-Deoxy analogues proved to be potent inhibitors of TMPKmt: 3'-CH(2)NH(2) (4), 3'-CH(2)N(3) (3), and 3'-CH(2)F (5) nucleotides exhibit the highest affinities within this series, with K(i) values of 10.5, 12, and 15 microM, respectively. These results show that TMPKmt tolerates the introduction of sterically demanding substituents at the 3'-position. Ribo analogues experience a significant affinity decrease, which is probably due to steric hindrance of Tyr103 in close vicinity of the 2'-position. Although the 5'-O-phosphorylated compounds have somewhat higher affinities for the enzyme, the parent nucleosides generally exhibit affinities for TMPKmt in the same order of magnitude and display a superior selectivity profile versus human TMPK. This series of inhibitors holds promise for the development of a new class of antituberculosis agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930144     DOI: 10.1021/jm021108n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Structural and chemical basis for enhanced affinity to a series of mycobacterial thymidine monophosphate kinase inhibitors: fragment-based QSAR and QM/MM docking studies.

Authors:  Renata V Bueno; Ney R Toledo; Bruno J Neves; Rodolpho C Braga; Carolina H Andrade
Journal:  J Mol Model       Date:  2012-07-31       Impact factor: 1.810

Review 2.  Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.

Authors:  Zhiyong Lou; Xiaoxue Zhang
Journal:  Protein Cell       Date:  2010-06-04       Impact factor: 14.870

3.  Computer-assisted combinatorial design of bicyclic thymidine analogs as inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.

Authors:  Vladimir Frecer; Pierfausto Seneci; Stanislav Miertus
Journal:  J Comput Aided Mol Des       Date:  2010-11-17       Impact factor: 3.686

4.  Structure-based in-silico rational design of a selective peptide inhibitor for thymidine monophosphate kinase of mycobacterium tuberculosis.

Authors:  Manoj Kumar; Sujata Sharma; Alagiri Srinivasan; Tej P Singh; Punit Kaur
Journal:  J Mol Model       Date:  2010-08-11       Impact factor: 1.810

Review 5.  Synthesis and structural activity relationship study of antitubercular carboxamides.

Authors:  D I Ugwu; B E Ezema; F U Eze; D I Ugwuja
Journal:  Int J Med Chem       Date:  2014-12-30

6.  1-(1-Arylethylpiperidin-4-yl)thymine Analogs as Antimycobacterial TMPK Inhibitors.

Authors:  Yanlin Jian; Fabian Hulpia; Martijn D P Risseeuw; He Eun Forbes; Guy Caljon; Hélène Munier-Lehmann; Helena I M Boshoff; Serge Van Calenbergh
Journal:  Molecules       Date:  2020-06-17       Impact factor: 4.411

Review 7.  Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors.

Authors:  Liudmila A Alexandrova; Anastasia L Khandazhinskaya; Elena S Matyugina; Dmitriy A Makarov; Sergey N Kochetkov
Journal:  Microorganisms       Date:  2022-06-27

8.  Anti-Mycobacterial Activity of Flavonoid and Pyrimidine Compounds.

Authors:  Saurabh Garg; Rakesh Kumar; Dennis Kunimoto; Gina R Rayat
Journal:  Molecules       Date:  2022-10-09       Impact factor: 4.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.